Acumen Pharmaceuticals, Inc. (ABOS) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

8/25

Growth 1 Margin 1 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

8
ABOS (Acumen Pharmaceuticals) Q2 2026: $110M Cash Position Supports Key Alzheimer’s Trial Readout and Pipeline Expansion
August 12, 2026
8
Acumen Pharma (ABOS) Q1 2026: $35.75M EBD Funding Extends Runway to 2027, Pipeline Optionality Builds
May 12, 2026
9
Acumen (ABOS) Q4 2025: EBD Platform Spurs $36M Raise as Brain Penetration Hits 40X in Preclinical
March 26, 2026
9
Acumen (ABOS) Q3 2025: $136M Cash Extends Runway Into 2027 as Phase 2 Alzheimer's Trial Progresses
November 12, 2025
9
Acumen Pharmaceuticals (ABOS) Q2 2025: $166M Cash Runway Extends to 2027 as EBD Pipeline Advances
August 12, 2025
8
Acumen Pharmaceuticals (ABOS) Q1 2025: $198M Cash Supports Rapid Phase 2 Progress Toward Late 2026 Readout
May 13, 2025
8
Acumen Pharmaceuticals (ABOS) Q4 2024: Phase 2 Enrollment Completes with $231M Cash Extending Runway into 2027
March 27, 2025
Acumen Pharmaceuticals (ABOS) Q3 2024: Altitude AD Enrollment Surges 75 Sites, Accelerating Phase 2 Momentum
November 12, 2024
Acumen Pharmaceuticals (ABOS) Q2 2024: ALTITUDE-AD Enrollment Surges Past Projections, Extending Runway for Next-Gen Alzheimer’s Antibody
August 13, 2024
Acumen Pharmaceuticals (ABOS) Q1 2024: R&D Spend Rises 54% as Altitude AD Phase 2 Launches
May 14, 2024
Acumen (ABOS) Q4 2023: $306M Cash Extends Runway, Phase 2 Altitude-AD Launches on Biomarker Momentum
March 26, 2024
Acumen (ABOS) Q3 2023: $50M Credit Bolsters Subcutaneous Alzheimer’s Antibody Push
November 13, 2023
Acumen Pharmaceuticals (ABOS) Q2 2023: $122M Capital Raise Extends Runway for Phase 2–3 Alzheimer’s Trial
August 08, 2023
Acumen (ABOS) Q1 2023: $184M Cash Extends Runway as ACU193 Phase 1 Data Nears
May 09, 2023
Acumen Pharmaceuticals (ABOS) Q4 2022: $193M Cash Extends Runway as ACU193 Phase 1 Hits Key Milestone
March 27, 2023

Browse all companies